AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ProKidney to present two posters at ASN Kidney Week 2025.
ByAinvest
Monday, Oct 20, 2025 7:39 am ET1min read
ProKidney Corp. will present two posters at ASN Kidney Week 2025, including a late-breaking poster on the Phase 2 REGEN-007 study results, focusing on renal autologous cell therapy in diabetes and chronic kidney disease. The company aims to showcase its efforts in developing cellular therapeutics for chronic kidney disease.
ProKidney Corp. (Nasdaq: PROK), a clinical-stage biotechnology company specializing in cell therapy platforms for chronic kidney diseases (CKD), has announced it will present two posters at the American Society of Nephrology (ASN) Kidney Week 2025. The event will be held from November 6 to 9, 2025, in Houston, Texas.The first poster, titled "Renal Autologous Cell Therapy in Diabetes and CKD," will feature the late-breaking results of the Phase 2 REGEN-007 study. This study focuses on the use of renal autologous cell therapy to treat diabetes and CKD. The presentation will provide insights into the effectiveness and safety of the therapy, which is part of ProKidney's lead product candidate, Renal Autologous Cell Therapy (REACT), as described in a .
The second poster, "Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel," will delve into the inflammatory profile of the cell therapy candidate rilparencel. This poster aims to showcase the company's advancements in regenerative medicine and its potential to revolutionize the treatment of CKD, as noted in a .
ProKidney, founded in 2015, has been at the forefront of developing innovative cellular therapies for CKD. The company's lead product candidate, REACT, is designed to preserve kidney function in patients with CKD. ProKidney is currently conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT, with a focus on treating moderate to severe diabetic kidney disease (DKD), as reported in the MarketScreener filing.
The presentations at ASN Kidney Week 2025 will provide valuable updates on ProKidney's progress in the development of cellular therapeutics for CKD. The company aims to showcase its efforts in advancing the field of regenerative medicine and its potential to improve the lives of patients with CKD.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet